Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Current Editions
Trump's threat to impose 25% pharma tariffs has alarmed biopharma companies, spurred talk of mitigation strategies
Politics, Policy & Law
With clinical records, patient samples and images in the millions, the diagnostics and data company is betting precision medicine can go multimodal
Product Development
Leaving past limitations behind, Danish pharma widens its technology aperture to brain shuttles, AI and more
Product Development
Epigenome editors could shine in neurology indications not served by other modalities — but only if companies invest in delivery
Editor's Commentary
Product Development
How Vertex is translating its success from CF into new areas, picking indication by indication, while leveraging AI
Emerging Company Profile
San Francisco Bay Area biotech has two antibody platforms designed to improve on the potency and safety of bispecifics
Market Access
But it’s unclear that market access will be affected
Data Byte
Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
After a takeout is announced, the target company’s share price hews much closer to the deal price without the CVR than with it
Shares of Wuxi Apptec and Wuxi Biologics are closing in on pre-Biosecure levels
Vyvgart sees strong growth with CIDP approval
Discovery & Translation
BioCentury’s roundup of translational innovations also includes boosting T cell antitumor activity via fructose, and a new Parkinson’s risk gene
Regulation
Non-GAAP profitability in sight as RNAi therapeutic adds cardiomyopathy indication alongside previous amyloidosis approval
Politics, Policy & Law
Trump administration personnel policies are driving experienced staff to quit
Finance
Following eight-year ‘pilot experiment’ in Italy, the firm’s Biovelocita now builds companies across Europe
Former GSK vaccines head Slaoui becomes chairman as Seattle start-up advances shingles shot that may confer tolerability benefit
Plus: SV Health Investors hits $250M goal for second Dementia Discovery Fund
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Politics, Policy & Law
Management Tracks
BioCentury ISSN 1097-7201